Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19
Launched by BAQIYATALLAH MEDICAL SCIENCES UNIVERSITY · Jul 8, 2020
Trial Information
Current as of June 01, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Conscious consent to participate in the study
- • Patients 18 to 75 years of age with COVID-19 who have been diagnosed with PCR.
- • Strong clinical suspicion of covid 19 with positive findings in CT Scan
- • Shortness of breath
- Exclusion Criteria:
- • Patients with HIV
- • Patients with cancer undergoing chemotherapy
- • Patients receiving Immune Mediators
- • Patients need hospitalization in the intensive care unit
- • Patients with uncontrolled heart, kidney or liver failure
- • Pregnant or lactating women
- • Intolerance to the drugs used in this study (symptoms such as diarrhea, nausea, vomiting and respiratory problems)
About Baqiyatallah Medical Sciences University
Baqiyatallah Medical Sciences University is a distinguished institution dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, the university emphasizes the integration of scientific inquiry and clinical practice, fostering an environment that supports the development of new therapies and medical technologies. With a commitment to ethical standards and patient safety, Baqiyatallah Medical Sciences University collaborates with a network of healthcare professionals and researchers to address pressing medical challenges, ultimately aiming to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials